Pharmafile Logo
Pharmafocus logo
Advanced Search

Yervoy

Showing 15 posts of 56 posts found.

Shire and BMS secure NICE recommendations for oncology drugs

July 27, 2016
Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …

News

BMS names Fouad Namouni as new oncology development head

July 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo

Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …

Appointment
lab

AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo

July 26, 2016
Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t

AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …

News
FDA building

FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo

January 25, 2016
Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer

The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …

News
Yervoy

FDA approves Bristol-Myers Squibb’s skin cancer drug

October 29, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilumumab, melanoma

The FDA has recommended Bristol-Myers Squibb’s cancer drug Yervoy (ipilimumab) for the adjuvant treatment of patients with melanoma. The drug, …

News
yervoy image

BMS immunotherapy combination impresses at ASCO

June 1, 2015
Research and Development, Sales and Marketing ASCO, BMS, Yervoy, opdivo

Bristol-Myers Squibb has presented data showing that a combination of its immunotherapies Opdivo and Yervoy significantly increases survival in advanced …

News
Opdivo

EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …

News
Keytruda image

Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival

March 25, 2015
Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab

A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …

News
Giovanni Caforio image

BMS names operating officer as new chief executive

January 21, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Giovanni Caforio, Lamberto Andreotti, Yervoy, opdivo

Bristol-Myers Squibb’s chief operating officer Giovanni Caforio will be stepping in to Lamberto Andreotti’s shoes as chief executive from May …

News

GSK melanoma drug sees quick NICE nod

September 18, 2014
Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer

NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …

News
merck image

BMS sues Merck over new melanoma drug

September 8, 2014
Research and Development, Sales and Marketing BMS, FDA, Merck, PD-1 inhibitors, Yervoy, keytruda

Things are getting ugly between Bristol-Myers Squibb and Merck as the former company began legal proceedings against the latter over …

News
BMS image

Bristol-Myers Squibb: following the string of pearls

September 8, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, BMS, GSK, Johanna Mercier, Pfizer, UCB, Yervoy, acquisitions

Bristol-Myers Squibb (BMS) is something of an enigma in the pharma industry. Whilst many of its big pharma peers are …

Feature

NICE and market access: time for reform?

August 26, 2014
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Bristol-Myers Squibb, NICE, Yervoy, reform

Earlier in the year, at the ABPI’s annual conference, the UK pharma lobby group released a new report suggesting that …

Feature
Kadcyla packshot

Storm brewing over Roche cancer drug price

August 8, 2014
Medical Communications, Research and Development, Sales and Marketing Cancer, Haslam, Kadcyla, NICE, Roche, Yervoy, rejection

The Breakthrough Breast Cancer charity and England’s drug pricing watchdog NICE have both attacked Roche for not lowering the price …

News
Yervoy image

NICE ‘yes’ for cancer drugs

July 23, 2014
Sales and Marketing Astellas, BMS, Cancer, NICE, Xtandi, Yervoy

Two big-name oncology brands, Bristol-Myers Squibb’s Yervoy and Astellas Pharma’s Xtandi, have been given the nod by drug costs watchdog …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026